{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-25-000025","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.742006+00:00","generated_at":"2026-05-22T23:50:58.200245+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Rad Q1 revenue falls 4% to $585M; full-year 2025 outlook moderated on uncertainty","bullets":["Revenue $585.4M, down from $610.8M YoY; GAAP gross margin 52.3% vs 53.4%.","GAAP net income $64.0M ($2.29 EPS) vs $383.9M ($13.45 EPS) in Q1 2024.","Non-GAAP net income $71.0M ($2.54 EPS) vs $65.3M ($2.30 EPS) YoY.","CEO cites market uncertainty; moderating full-year 2025 outlook.","Non-GAAP gross margin 53.8%, slightly down from 54.2% a year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-25-000025","json":"https://secwatch.observer/filing/0000012208-25-000025.json","markdown":"https://secwatch.observer/filing/0000012208-25-000025.md","text":"https://secwatch.observer/filing/0000012208-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000025/0000012208-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000025/bio-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T23:50:58.200245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}